PTJ
NRIX icon

Paul Tudor Jones’s Nurix Therapeutics NRIX Stock Holding History

Paul Tudor Jones’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,760
Closed -$659K – 4084
2025
Q4 		$659K Sell
34,760
-3,183
-8% -$45.7K ﹤0.01% 2553
2025
Q3 		$351K Buy
+37,943
New +$394K ﹤0.01% 2882
2024
Q4 		– Sell
-22,259
Closed -$500K – 3360
2024
Q3 		$500K Buy
22,259
+211
+1% +$4.78K ﹤0.01% 2036
2024
Q2 		$460K Buy
+22,048
New +$343K ﹤0.01% 1841
2024
Q1 		– Sell
-22,071
Closed -$228K – 2609
2023
Q4 		$228K Buy
+22,071
New +$151K ﹤0.01% 2151
2023
Q3 		– Sell
-12,991
Closed -$130K – 2681
2023
Q2 		$130K Sell
12,991
-9,115
-41% -$93K ﹤0.01% 2279
2023
Q1 		$196K Sell
22,106
-56
-0.3% -$584 ﹤0.01% 2184
2022
Q4 		$243K Sell
22,162
-35
-0.2% -$422 ﹤0.01% 2033
2022
Q3 		$289K Buy
22,197
+1,848
+9% +$29.2K 0.01% 1817
2022
Q2 		$258K Sell
20,349
-2,200
-10% -$24.9K 0.01% 1665
2022
Q1 		$316K Sell
22,549
-2,300
-9% -$40.8K 0.01% 1524
2021
Q4 		$719K Buy
+24,849
New +$753K 0.01% 1215

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Paul Tudor Jones's NRIX Position: Q1 2026 in Review

Paul Tudor Jones sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 34,760 shares — an estimated $659K sold.

Paul Tudor Jones first reported a position in NRIX in Q4 2021 and held it in 12 quarters. The position peaked at $719K in Q4 2021. 196 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Paul Tudor Jones reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 34,760 Nurix Therapeutics shares in Q1 2026, an estimated $659K.
  • Paul Tudor Jones first reported a position in Nurix Therapeutics in Q4 2021 and held it in 12 quarters.
  • Paul Tudor Jones's Nurix Therapeutics position peaked at $719K in Q4 2021.
  • 196 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.